Pharmacyclics Inc (PCYC) 163.28 $PCYC
Actavis Leads IBD 50 Stocks With Earnings This Week
at Investor's Business Daily - 1 hr 43 mins ago
Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today's IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), PCYC: 163.28 (+0.23), AKRX: 47.28 (-0.25), JAZZ: 169.69 (+6.89), IPGP: 87.26 (+0.07)
Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Thu Feb 12, 9:40AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for the fourth quarter and full year 2014 on Wednesday, February 18, 2015 at 4:30 P.M. Eastern Time. A press release of the results will be released shortly after markets close on the day of the conference call.
PCYC: 163.28 (+0.23)
Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)
Comments On Gilead's Quarter And The Road Ahead
DoctoRx - at Seeking Alpha - Wed Feb 11, 11:57AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
Uptrend Call Working As Pharmacyclics Stock Rises 12.7% (PCYC)
Comtex SmarTrend(R) - Mon Feb 09, 9:59AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 4 weeks, Pharmacyclics has returned 12.73% as of today's recent price of $166.02.
PCYC: 163.28 (+0.23)
3 Drugs That Could Become Blockbusters in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 2:02PM CST
Source: Flickr user Chris Potter A study by McKinsey & Company found that analysts' peak sales projections for drugs under development typically miss the mark -- by a lot. More than 60% of 1,700 sales forecasts made on 260 drugs launched...
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16)
Can You Guess the Stock Putting Gilead Sciences to Shame? (Hint: It's Not AbbVie)
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 5:35AM CST
Source: Gilead Sciences When you hear "Gilead Sciences," I know many people think, "AbbVie" -- the two have certainly been connected in headlines lately. And The FDA approval of AbbVie's hepatitis C drug Viekira Pak could mean that AbbVie takes...
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56)
Pharmacyclics Larger Than S&P 500 Component Lam Research
TheOnlineInvestor.com - Fri Feb 06, 3:41PM CST
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Pharmacyclics, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Lam Research Corp , according to The...
PCYC: 163.28 (+0.23)
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)
Can Edwards Lifesciences (EW) Surprise Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 11:20AM CST
Edwards Lifesciences (EW) has delivered positive earnings surprises in all the past four quarters with an average beat of 11.70%
IPXL: 39.51 (+0.69), PCYC: 163.28 (+0.23), EW: 134.23 (+1.89), HUM: 152.67 (-1.06)
Some Pre-Earnings Release Observations About Gilead Sciences
DoctoRx - at Seeking Alpha - Mon Feb 02, 10:02AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IBB: 323.46 (+3.04), ABBV: 58.05 (+1.00)
Pharmacyclics Has Returned 15.1% Since SmarTrend Recommendation (PCYC)
Comtex SmarTrend(R) - Mon Feb 02, 9:33AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 3 weeks, Pharmacyclics has returned 15.11% as of today's recent price of $169.52.
PCYC: 163.28 (+0.23)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 4:55PM CST
Pharmacyclics' (PCYC) Imbruvica gained FDA approval for all lines of therapy for the treatment of patients suffering from Waldenstrom's macroglobulinemia.
LCI: 57.78 (-0.91), JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), BIOD: 1.38 (-0.14)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
3 Biotechs Looking Good this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 11:38AM CST
A number of biotech companies are seeing improvements in their financial results.
BCRX: 10.06 (-0.09), PCYC: 163.28 (+0.23), ARIA: 7.35 (+0.45)
FDA clears Imbruvica expanded label
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:22AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23)
U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)
PR Newswire - Thu Jan 29, 10:43AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA® (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma.1 This is the fourth indication for IMBRUVICA, an oral therapy, which received FDA Breakthrough Therapy Designation for this indication in February 2013. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
PCYC: 163.28 (+0.23)
Pharmacyclics Set to Possibly Pullback After Yesterday's Rally of 5.57%
Comtex SmarTrend(R) - Mon Jan 26, 4:30PM CST
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $158.01 to a high of $167.73. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $159.99 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PCYC: 163.28 (+0.23)
Actavis Leads IBD 50 Stocks With Earnings This Week
at Investor's Business Daily - 1 hr 43 mins ago
Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today's IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), PCYC: 163.28 (+0.23), AKRX: 47.28 (-0.25), JAZZ: 169.69 (+6.89), IPGP: 87.26 (+0.07)
Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Thu Feb 12, 9:40AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for the fourth quarter and full year 2014 on Wednesday, February 18, 2015 at 4:30 P.M. Eastern Time. A press release of the results will be released shortly after markets close on the day of the conference call.
PCYC: 163.28 (+0.23)
Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)
Comments On Gilead's Quarter And The Road Ahead
DoctoRx - at Seeking Alpha - Wed Feb 11, 11:57AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
Uptrend Call Working As Pharmacyclics Stock Rises 12.7% (PCYC)
Comtex SmarTrend(R) - Mon Feb 09, 9:59AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 4 weeks, Pharmacyclics has returned 12.73% as of today's recent price of $166.02. PCYC: 163.28 (+0.23)
3 Drugs That Could Become Blockbusters in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 2:02PM CST
Source: Flickr user Chris Potter A study by McKinsey & Company found that analysts' peak sales projections for drugs under development typically miss the mark -- by a lot. More than 60% of 1,700 sales forecasts made on 260 drugs launched...
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16)
Can You Guess the Stock Putting Gilead Sciences to Shame? (Hint: It's Not AbbVie)
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 5:35AM CST
Source: Gilead Sciences When you hear "Gilead Sciences," I know many people think, "AbbVie" -- the two have certainly been connected in headlines lately. And The FDA approval of AbbVie's hepatitis C drug Viekira Pak could mean that AbbVie takes...
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56)
Pharmacyclics Larger Than S&P 500 Component Lam Research
TheOnlineInvestor.com - Fri Feb 06, 3:41PM CST
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Pharmacyclics, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Lam Research Corp , according to The...
PCYC: 163.28 (+0.23)
Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)
Can Edwards Lifesciences (EW) Surprise Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 11:20AM CST
Edwards Lifesciences (EW) has delivered positive earnings surprises in all the past four quarters with an average beat of 11.70%
IPXL: 39.51 (+0.69), PCYC: 163.28 (+0.23), EW: 134.23 (+1.89), HUM: 152.67 (-1.06)
Some Pre-Earnings Release Observations About Gilead Sciences
DoctoRx - at Seeking Alpha - Mon Feb 02, 10:02AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IBB: 323.46 (+3.04), ABBV: 58.05 (+1.00)
Pharmacyclics Has Returned 15.1% Since SmarTrend Recommendation (PCYC)
Comtex SmarTrend(R) - Mon Feb 02, 9:33AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 3 weeks, Pharmacyclics has returned 15.11% as of today's recent price of $169.52. PCYC: 163.28 (+0.23)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 4:55PM CST
Pharmacyclics' (PCYC) Imbruvica gained FDA approval for all lines of therapy for the treatment of patients suffering from Waldenstrom's macroglobulinemia.
LCI: 57.78 (-0.91), JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), BIOD: 1.38 (-0.14)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
3 Biotechs Looking Good this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 11:38AM CST
A number of biotech companies are seeing improvements in their financial results.
BCRX: 10.06 (-0.09), PCYC: 163.28 (+0.23), ARIA: 7.35 (+0.45)
FDA clears Imbruvica expanded label
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:22AM CST
JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23)
U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)
PR Newswire - Thu Jan 29, 10:43AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA® (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma.1 This is the fourth indication for IMBRUVICA, an oral therapy, which received FDA Breakthrough Therapy Designation for this indication in February 2013. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
PCYC: 163.28 (+0.23)
Pharmacyclics Set to Possibly Pullback After Yesterday's Rally of 5.57%
Comtex SmarTrend(R) - Mon Jan 26, 4:30PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $158.01 to a high of $167.73. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $159.99 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PCYC: 163.28 (+0.23)
